Results 101 to 110 of about 315,615 (312)
Laryngoscope Investigative Otolaryngology, 2020 Background Head and neck squamous cell carcinoma (HNSCC) has been rising in incidence primarily related to HPV‐associated oropharyngeal cancers. Novel molecular therapeutics are evolving with the mTOR pathway as a new target.
Jaimin Patel +5 more
doaj +1 more source
Journal of the American Medical Association, 1948 III. CANCER OF THE LARYNX Anatomically the larynx extends from the tip of the epiglottis to the inferior margin of the cricoid cartilage, and the term cancer of the larynx, therefore, includes all malignant growths arising in the epiglottis, the aryepiglottic folds, the arytenoids, the ventricular bands, the ventricles, the vocal cords, the subglottic
openaire +3 more sources
Advanced Science, EarlyView.ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.
Yue Li +8 more
wiley +1 more source
Identification of Lethal microRNAs Specific for Head and Neck Cancer
, 2013 Purpose: The prognosis of head and neck squamous cell carcinomas (HNSCC) remains disappointing and the development of novel anti-cancer agents is urgently awaited.
de Kemp, S.R. +10 more
core +1 more source
Chemoprevention of Head and Neck Cancer
Otolaryngology–Head and Neck Surgery, 2000 Increasing emphasis has been placed on chemoprevention as understanding of the genetic and molecular events of carcinogenesis has evolved. More than 1000 compounds that inhibit cancer development in vitro or in animal models have been identified, and active research is under way to determine which of these agents will be both effective and nontoxic in ...
Armstrong, William B, Meyskens, Frank L
openaire +4 more sources
Advanced Science, EarlyView.ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley +1 more source
Secondary head and neck cancer in patients with history of hematological malignancy
, 2013 Background: Head and neck cancer is a common second cancer in patients with a history of hematological malignancies. The purpose of this study was present the clinical characteristics and treatment outcomes of this group of patients.
Chan, JYW +6 more
core +1 more source
Advanced Science, EarlyView.ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs +4 more
wiley +1 more source
, 2008 Introduction: Gefitinib, an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces growth arrest in squamous cancer cell carcinoma of head and neck (SCCHN) cell lines mainly by blocking cells in G1 and preventing them ...
Romano, Carmela
core
AHNAK and inflammatory markers predict poor survival in laryngeal carcinoma. [PDF]
, 2012 AHNAK/Desmoyokin is a giant protein which has been recently linked to reorganization of the actin cytoskeleton, cellular migration and invasion. Here, we investigated the role of AHNAK in the pathophysiology of larynx carcinoma-one of the major subtypes ...
Reinhard Zeidler +13 more
core +1 more source